Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17479324 | 0.87 | TSHR (0.38) | TSHRTDP1SMN1; SMN2HTTMAPK1 | |
| SCHEMBL17479705 | 0.86 | HSD17B10 (0.42) | TSHRTDP1SMN1; SMN2HTTMAPK1 | |
| SCHEMBL17479697 | 0.80 | MAPK1 (0.38) | TSHRTDP1SMN1; SMN2HTTMAPK1 | |
| SCHEMBL17479006 | 0.80 | SMN1; SMN2 (0.43) | TSHRSMN1; SMN2HTTMAPK1MAPT | |
| SCHEMBL17479707 | 0.78 | PSEN1 (0.39) | TSHRTDP1HTTMAPK1MAPT | |
| SCHEMBL17479172 | 0.77 | SMN1; SMN2 (0.42) | TSHRSMN1; SMN2HTTMAPK1MAPT | |
| SCHEMBL17479698 | 0.74 | SMN1; SMN2 (0.44) | TSHRSMN1; SMN2HTTMAPK1MAPT | |
| SCHEMBL17479756 | 0.74 | MAPT (0.51) | TSHRTDP1SMN1; SMN2MAPK1MAPT | |
| SCHEMBL17479667 | 0.74 | MMP2 (0.45) | TSHRSMN1; SMN2MAPK1MAPTALDH1A1 | |
| SCHEMBL17479376 | 0.73 | NPC1 (0.45) | TSHRSMN1; SMN2HTTMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | claimed |
| US-10065937-B2 | FLT3 receptor antagonists | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-04 | — | — | US | claimed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | claimed |
| EP-3174859-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2017-06-07 | — | — | EP | claimed |
| WO-2016016370-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-02-04 | — | — | WO | claimed |
| CN-107001283-B | FLT3 receptor antagonists | 国家健康与医学研究院 | 2021-05-25 | — | — | CN | disclosed |
| US-20200171022-A1 | FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-06-04 | — | — | US | disclosed |
| CN-111093640-A | FLT3 inhibitors for improving opioid pain therapy | 国家健康与医学研究院 | 2020-05-01 | — | — | CN | disclosed |
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | disclosed |
| EP-3624780-A1 | FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018211018-A1 | FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-11-22 | — | — | WO | disclosed |
| US-10065937-B2 | FLT3 receptor antagonists | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-04 | — | — | US | disclosed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | disclosed |
| EP-3174859-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016370-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | FLT3, CSF1R, CSF3R | TSHR 69/4885TDP1 2190/4885SMN1; SMN2 3517/4885 |
| US-10065937-B2 | FLT3 receptor antagonists | FLT3, CSF1R, CSF3R | TSHR 69/4885TDP1 2190/4885SMN1; SMN2 3517/4885 |
| US-20200171022-A1 | FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS | FLT3, CSF1R, OPRL1 | TSHR 2361/4885TDP1 3796/4885SMN1; SMN2 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.